FDA Grants Orphan Drug Designation to BRC's Pancreatic Cancer Treatment
What happened
The FDA granted Orphan Drug Designation to Nuzefatide pevedotin for the treatment of pancreatic cancer. Bicycle Therapeutics plc reported financial results for the third quarter ended September 30, 2026, noting that the designation supports its strategy. The company also stated that the first company-sponsored radioligand clinical trial for BT1702 is expected in the second half of 2027.
From finanznachrichten.de
Why it matters
The designation provides regulatory incentives and market exclusivity for BRC's drug in the United States of America. Bicycle Therapeutics plc reported cash and cash equivalents of $469.9 million as of September 30, 2026, with an expected cash runway extending into 2030.
From finanznachrichten.de
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- BRCSpeculative
BRC might see increased revenue and market exclusivity for Nuzefatide pevedotin due to the regulatory designation.
Keep exploring
The entities involved
Related events
- The FDA granted Orphan Drug Designation to sovleplenib, a drug associated with HUTCHMED, which operates in China.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- FDA approval expands patient access to therapies for ACCORD.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.